Skip To Content

Participating in open and frank conversations can be a catalyst for both positive change and a better industry. As we share our perspective you will find:

  • Relevant and timely industry information
  • Medication trends, and their impact
  • Case studies, and the results of their related projects
  • Special-subject on-demand webinars

Articles and blogs 

Sharing information with the industry is an important part of our mission. Our subject matter experts translate today’s news into comprehensive informational pieces to help you better understand the impact of a recent industry update, trend, or issue.

September 03, 2020 · Public Policy & Regulatory Affairs Team
In the late hours of the legislative session, the California Assembly and Senate reached a compromise and passed a COVID-19 workers’ compensation presumption bill. After considering several various pieces of presumption legislation, the Legislature passed SB 1159, which creates a presumption and addresses the impact of COVID-19 on the workers’ compensation system. It is expected to be signed by the governor. Read more...
August 30, 2020 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more...
August 13, 2020 · Optum Workers' Comp and Auto No-fault
A new injectable opioid analgesic, Olinvyk™ (oliceridine), was approved by the U.S. Food and Drug Administration (FDA) on August 7, 2020. Olinvyk is indicated to manage acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Read more...
August 09, 2020 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more...
August 06, 2020 · Optum Workers' Comp and Auto No-fault
Previously proposed Michigan auto no-fault utilization review (UR) rules (which were required by last year’s reform legislation) have moved to the next phase of the formal rule-making process, which is required review by a state legislative committee. Unless there are committee objections, the latest version, amended after comments by the state’s Department of Insurance and Financial Services (DIFS), should be adopted in the near future. Read more...
August 03, 2020 · Clinical Connection team
In late July, the U.S. Food and Drug Administration (FDA) announced they are requiring manufacturers of all opioid analgesics and medications to treat opioid use disorder (OUD) to add recommendations about naloxone to the prescribing information and patient Medication Guides. Read more...
<< Previous      Next >>
Page 2 of 17

Subscribe today to receive our latest blogs, articles and more.